Abstract
Sarcoidosis is a chronic systemic disease of unknown origin and uncertain prognosis that most commonly affects young adults, and frequently presents with bilateral hilar lymphadenopathy, pulmonary infiltrates and ocular and skin lesions. The diagnosis is established when characteristic clinical-radiological features are supported by compatible histopathology of epithelioid cell granulomas, following exclusion of known causes of granulomatous inflammation. Indeed, sarcoidosis belongs to a large family of disorders that share granuloma formation as common denominator. Since its first description by Jonathan Hutchinson in 1869, sarcoidosis has generated enormous interest and considerable controversy. In Hutchinson’s day, it was considered a dermatological condition, which gradually evolved into a multisystem disorder associated in the majority of cases with respiratory abnormalities. With time, it has also become clear that sarcoidosis occurs throughout the world, affecting individuals of both genders and all races, although its prevalence varies widely across ethnic and racial groups. In recent years, advances in different disciplines, particularly biochemistry, genetics, immunology and molecular biology, have improved dramatically our understanding of the disease. Yet, the critical questions regarding who gets sarcoidosis and whether it has an infectious origin remain unanswered. Sarcoidosis has a distinguished medical history that covers the last 150 years. Right from the time of seminal contributions by Hutchinson, Besnier and Boeck medical discussion on sarcoidosis has always been animated and to a certain extent emotional. Such discussions will inevitable continue until the true cause of the disease has been found, hopefully in the near future.
Similar content being viewed by others
References
Sharma OP (2005) Definition and history of sarcoidosis. Eur Respir Mon 32:1–12
Hutchinson J (1898) Mortimer's malady. A form of lupus pernio. Arch Surg (London) 9:307–315
Besnier E (1889) Lupus Pernio de la Face. Ann Derm Syph (Paris) 10:33–36
Boeck C (1899) Multiple benign sarcoid of the skin. Norsk Mag Laegevid 14:1321–1345
Heerfordt CF (1909) Uber eine febris uveo-parotidea subchronica. Graefes Arch Ophthalmol 70:254–258
Schaumann J (1933) Etude anatomo pathologique et histologique sur les localisations viscerales de la lymphogranulomatose benigne. Bull Soc Fr Dermatol Syphiligr 1:167–322
Lofgren S (1953) Primary pulmonary sarcoidosis. Acta Med Scand 145:424–455
Kveim A (1941) On a new and specific cutaneous reaction in Boeck's sarcoid: a preliminary report. Nord Med 9:169–172
Siltzbach LE (1961) The Kveim test in sarcoidosis: a study of 750 patients. J Am Med Ass 178:476–482
Zissel G (2014) Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 35:307–315
Noor A, Knox KS (2007) Immunopathogenesis of sarcoidosis. Clin Dermatol 25:250–258
Spagnolo P, Grunewald J (2013) Recent advances in the genetics of sarcoidosis. J Med Genet 50:290–297
Newman LS, Rose CS, Maier LA (1997) Sarcoidosis. N Engl J Med 336:1224–1234
Spagnolo P, Richeldi L, du Bois RM (2008) Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. Semin Respir Crit Care Med 29:610–619
Statement on Sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. (1999). Am J Respir Crit Care Med. 160, 736-755
Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145:234–241
Grunewald J, Eklund A (2009) Löfgren’s syndrome. Human Leukocyte Antigen strongly influences the disease course. Am J Respir Crit Care Med 179:307–312
Spagnolo P, du Bois RM (2007) Genetics of sarcoidosis. Clin Dermatol 25:242–249
Newman LS (2005) Aetiologies of sarcoidosis. Eur Respir Mon 32:23–48
Judson MA (2003) The etiologic agent of sarcoidosis. What if there isn’t one? Chest 124:6–8
Compliance with Ethical Standards
ᅟ
Conflicts of Interest
Paolo Spagnolo serves as consultant for Roche and has received consulting fees from Boehringer Ingelheim.
Informed Consent
As there is no person or personal data appearing in the paper, there is no one from whom a permission should be obtained in order to publish personal data.
Research Involving Human Participants and/or Animals
This article does not contain any studies with human or animal subjects performed by the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spagnolo, P. Sarcoidosis: a Critical Review of History and Milestones. Clinic Rev Allerg Immunol 49, 1–5 (2015). https://doi.org/10.1007/s12016-015-8480-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-015-8480-0